Navigation Links
Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annual Meeting
Date:5/15/2008

r cancer and in more than 70 countries for the treatment of patients with advanced kidney cancer. Nexavar is also being evaluated by the companies, international study groups, government agencies and individual investigators as a single agent or combination treatment in a wide range of cancers, including metastatic melanoma, lung cancer, breast cancer and as an adjuvant therapy for kidney cancer.

Important Safety Considerations For Patients Taking Nexavar

Based on the currently approved U.S. package insert for the treatment of patients with unresectable hepatocellular carcinoma and advanced kidney cancer, hypertension may occur early in the course of therapy and blood pressure should be monitored weekly during the first six weeks of therapy and treated as needed. In HCC patients, bleeding with a fatal outcome from any site was reported in 2.4% for Nexavar and 4% in placebo. The incidence of treatment-emergent cardiac ischemia/infarction was 2.7% for Nexavar vs. 1.3% for placebo. In RCC patients, incidence of bleeding regardless of causality was 15% for Nexavar vs. 8% for placebo and the incidence of treatment-emergent cardiac ischemia/infarction was 2.9% for Nexavar vs. 0.4% for placebo. Most common adverse events >/=20% related to Nexavar for both HCC and RCC were fatigue, weight loss, rash/desquamation, hand-foot skin reaction, alopecia, diarrhea, nausea, and abdominal pain. Grade 3/4 adverse events in HCC and RCC patients, respectively, were 45% for Nexavar vs. 32% for placebo and 38% for Nexavar and 28% for placebo. Women of child-bearing potential should be advised to avoid becoming pregnant and advised against breast-feeding. In cases of any severe or persistent side effects, temporary treatment interruption, dose modification or permanent discontinuation should be considered.

About Bayer HealthCare Pharmaceuticals Inc.

Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals unit of Bayer HealthCare LLC, a division o
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; OnyxPharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Bayer CropSciences Vegetable Seed Business Nunhems Acquires US Lettuce Seed Company Paragon Seed
2. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
3. Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)
4. Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement
5. Accelerated Community Oncology Research Network, Inc. (ACORN), Initiates a Phase 2b Metastatic Breast Cancer Trial in Cooperation With Bayer and Onyx
6. Bayer HealthCare Pharmaceuticals Introduces VistaTrak(TM) an Innovative Contrast Media Management System
7. Bayer HealthCare Affiliate MEDRAD Successfully Completes Tender Offer for Shares of Possis Medical; Announces Subsequent Offering Period
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014 According to ... (Consumables, Instruments, Services), Methods (Phenotypic, Genotypic), Applications (Pharmaceutical, Diagnostic, ... Characterization) - Global Forecasts to 2019" published ... estimated at $896.5 Million in 2014 and ... 2019, growing at a CAGR of 5.9% ...
(Date:7/28/2014)... , July 28, 2014   Propeller Health , ... announced the hire of Brad Towle as ... be responsible for driving the company,s sales growth, customer ... in healthcare, and specifically his past role in the ... the company at this pivotal time in the industry," ...
(Date:7/28/2014)... The global market for biotechnology is expected ... a new study by Grand View Research, Inc. Increasing ... vaccines and drugs in an attempt to improve healthcare ... to drive market demand over the next six years. ... the use of genetically engineered seeds is expected to ...
(Date:7/28/2014)... Research and Markets has announced the ... report to their offering. ... technique used to determine the size of a particle in ... to analyze the size of particles as it can affect ... performed to determine the behavior and nature of a material, ...
Breaking Biology Technology:Microbial Identification Market worth $1,194.1 Million by 2019 2Microbial Identification Market worth $1,194.1 Million by 2019 3Propeller Health Hires Brad Towle as Senior Vice President of Business and Client Development 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 3Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 4Global Particle Size Analysis Market 2014-2018 2
... , , ... Tobira Therapeutics Inc., a clinical stage biotechnology company committed ... life-threatening and life-altering infectious diseases, today announced pharmacokinetic data ... of TBR-652 in sixty healthy volunteers. TBR-652, a ...
... CAMBRIDGE, Mass., Sept. 14 Ironwood Pharmaceuticals, Inc. today ... officer and senior vice president of marketing and sales. Mr. McCourt ... lead Ironwood,s growing marketing and sales team. , , ... , Mr. McCourt comes to Ironwood from Amgen, where ...
... , , , JOHNSON CITY, ... Rx100, a potent radioprotectant as well as radiomitigator, protects against lethal, ... after exposure. , , In recent experiments, ... subcutaneous dose at either 48 or 72 hours after lethal, whole-body ...
Cached Biology Technology:Tobira Therapeutics Inc. Announces Phase I Pharmacokinetic Data of TBR-652 for the Treatment of HIV 2Ironwood Appoints Thomas McCourt As Chief Commercial Officer and Senior Vice President of Marketing and Sales 2Rx100 Rescues Life if Administered Up to 72 Hours After Exposure to Lethal, Whole-Body Radiation! 2
(Date:7/28/2014)... 28, 2014)The Brain & Behavior Research Foundation today ... Freedman Prizes, recognizing exceptional clinical and basic research ... NARSAD Young Investigator Grants. The grants enable early ... and psychosocial research for the prevention, early detection, ... one in four people. , Six young scientistswinners ...
(Date:7/28/2014)... Inspired Engineering at Harvard University today announced that ... a newly formed private company to accelerate development ... The announcement follows a worldwide license ... and the start-up Emulate Inc., relating to the ... , "This is a big win towards ...
(Date:7/27/2014)... one of the largest prevalence studies to date, researchers ... prevalence estimates for the hepatitis C virus (HCV). Findings ... for the Study of Liver Diseases, indicate that genotype ... million patients infected of which one-third reside in East ... is the next most prevalent, followed by genotypes 2, ...
Breaking Biology News(10 mins):The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 2The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 3The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 4Wyss Institute's technology translation engine launches 'Organs-on-Chips' company 2Wyss Institute's technology translation engine launches 'Organs-on-Chips' company 3Hepatitis C virus genotype 1 is most prevalent worldwide 2
... Ind. - As the United Nations climate negotiations proceed ... toward quantifying the "socioclimatic" exposure of different countries to ... University and the Abdus Salam International Centre for Theoretical ... the United States - major greenhouse gas-emitting nations that ...
... $50 billion in manufactured goods last year, according to ... $2.6 trillion. By 2011, over $15 billion in nano-enabled ... $3 billion in 2006. And industry experts project that ... consumer food products by 2010. Yet, ...
... from the Early Jurassic has been discovered in Antarctica. ... hammeri and lived about 190 million years ago. , ... based on partial foot, leg and ankle bones found ... at an elevation of more than 13,000 feet. , ...
Cached Biology News:Scientists develop new measure of 'socioclimactic' risk 2Scientists develop new measure of 'socioclimactic' risk 3Scientists develop new measure of 'socioclimactic' risk 4FDLI, PEN co-sponsor major conference on nanotechnology 2FDLI, PEN co-sponsor major conference on nanotechnology 3Massive dinosaur discovered in Antarctica sheds light on life, distribution of sauropodomorphs 2
2'-Fluorine-CTP (2'-F-CTP) is readily incorporated into transcripts by T7 and SP6 R&DNA™ Polymerase and is available separately....
... J. Karn (1995) This volume ... and methods for the study of major ... reverse transcriptase, ribonuclease H, integrase and protease. ... binding assays; Tat and Rev assays; HIV/CD4 ...
Human Glypican 2 Biotinylated Affinity Purified PAb...
Human Contactin-2/TAG1 Affinity Purified Polyclonal Ab...
Biology Products: